Research: Laboratory Program –
David M. Goldenberg, Sc.D., M.D.

Dr. Goldenberg is the founder and President of the Garden State Cancer Center. He received his Sc.D. from the University of Erlangen-Nuremberg Faculty of Natural Sciences in 1964 and his M.D. from the University of Heidelberg School of Medicine in 1966. Dr. Goldenberg has received numerous awards, both nationally and internationally including twice receiving an "Outstanding Investigator Award from the National Cancer Institute, the New Jersey Assembly and Senate "Awards for Excellence in Cancer Research" and the New Jersey Pride Award in Science and Technology" from NJ Monthly. He currently holds editorial positions with several peer reviewed cancer research journals including "Tumor Biology", "Tumor Targeting", "Diagnostic Oncology" and the American Cancer Society's "Cancer".

Dr. Goldenberg has pioneered the development of radiolabeled antibodies for various applications in the detection, diagnosis, and therapy of cancer. Under his leadership, the scientists and clinicians at the Garden State Cancer Center have developed antibodies for the diagnosis and treatment of solid tumors such as colorectal, pancreatic, lung, melanoma breast, and ovarian, as well as certain hematologic cancers such as lymphoma and multiple myeloma. He has overseen the in-house clinic as well as clinical outreach at affiliated institutions for development of research opportunities in the treatment of cancer patients with radiolabeled antibodies.

1. Goldenberg, DM. Targeted therapy of cancer with radiolabeled antibodies.J. Nucl. Med., 43:693-713, 2002.
2. Chang, CH, Sharkey, RM, Rossi, EA, Karacay, H, McBride, W, Hansen HJ, Chatel, JF, Barbet, J, and Goldenberg, DM. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther. 1:553-563, 2002.
3. Tsai, DE, Schuster, SJ, Matthies, A, Moore, HC, Alavi, A, Juweid, ME, Goldenberg, DM, and Stadtmauer, EA. Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin. Lymphoma., 1:62-66, 2000.
4. Goldenberg, DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hematol., 39:195-201, 2001.
5. Behr, TM, Blumenthal, RD, Memtsoudis, S, Sharkey, RM, Gratz, S, Becker, W, and Goldenberg, DM. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin. Cancer. Res., 6:4900-4907, 2000.
6. Lechner, P, Lind, P, Goldenberg, DM. Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival? J. Am. Coll. Surg., 191:511-518, 2000.
7. Goldenberg, DM, Abdel-Nabi, H, Sullivan, CL, Serafini, A, Seldin, D, Barron, B, Lamki, L, Line, B, Wegener, WA. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer, 89:104-115, 2000.